Abbott $235 Mil. Biocompatibles Stent Purchase Includes Royalties Up To 6%
This article was originally published in The Gray Sheet
Executive Summary
Abbott's acquisition of the cardiovascular stent business of Biocompatibles International for $234.5 mil. in cash plus royalties will facilitate integration of Abbott's internally-developed, rapamycin analogue stent coating with Biocompatibles' BiodivYsio stent line
You may also be interested in...
Centerpulse Divestitures Could Make Remaining Firm Attractive To Acquirers
Centerpulse's plan to divest its cardiac and vascular divisions to focus on its core orthopedics business suggests that the Swiss firm may be positioning itself for an eventual sale to a larger player in that arena
Centerpulse Divestitures Could Make Remaining Firm Attractive To Acquirers
Centerpulse's plan to divest its cardiac and vascular divisions to focus on its core orthopedics business suggests that the Swiss firm may be positioning itself for an eventual sale to a larger player in that arena
Biocompatibles
British firm will return roughly $143.6 mil. ($1.01 per ordinary share) to shareholders following the March 18 acquisition of its stent manufacturing facility by Abbott Labs (1"The Gray Sheet" March 25, 2002, p. 3)...